chevron_leftBack
As of 13 June 2026, CalciMedica, Inc. has a market cap of $8.79M USD, ranking #41950 globally and #5403 in the United States.
It ranks #3714 in the Healthcare sector, and #728 in the Biotechnology industry.
Key Stats
Market Cap
$8.79MUSD
Enterprise Value
$5.62MUSD
EBITDA (TTM)
-$23.08MUSD
Net Income (TTM)
-$29.56MUSD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
A. Leheny
open_in_new
Employees
16
Founded
2011
Website
calcimedica.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -3.2% | -7.9% | -1.9% | -55% | -82% | -63% |
News
Loading...
CALC Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
CALC
CalciMedica Inc Ordinary Shares
ISIN: US38942Q2021
Shares Out.:
Shares Outstanding:
15.798M1
Shares Float:
9.274M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
0.5581 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
2M%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
2M%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
314K%
|
-
|
|
NYSE: IQV
|
$26.3B
299K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
285K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
206K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
544K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
510K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
482K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
481K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
320K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
292K%
|
-
|
chevron_leftBack